Drug intelligence / Profile preview

TXN siRNA

Development stage
Preclinical
Lead developer
Xi'an Jiaotong University
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

TXN siRNA is a small interfering RNA (siRNA) designed to silence the expression of the thioredoxin (TXN) gene. Thioredoxin is a critical antioxidant protein that plays a vital role in maintaining cellular redox homeostasis and protecting cells from oxidative stress. In multiple myeloma (MM) research, TXN has been identified as a key inhibitor of ferroptosis, a form of iron-dependent regulated cell death. By utilizing TXN siRNA to knockdown TXN expression, researchers have demonstrated increased lipid peroxidation and inhibited cell proliferation in MM cell lines, such as RPMI8226 and MM.1S. This suggests that the SLC7A11-IRF1-TXN axis serves as a defensive pathway against ferroptosis in cancer cells. Consequently, TXN siRNA serves as both a research tool to elucidate these pathways and a potential precursor to therapeutic strategies aimed at sensitizing resistant multiple myeloma cells to ferroptotic cell death.

Other names
thioredoxin siRNATXN-targeting siRNA
02

Targets

Innate immune RNA sensorsTXN (Thioredoxin-1)Thioredoxin mRNA (TXN mRNA)

Beyond the preview

Go deeper on TXN siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TXN siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call